Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2019

Oct 02, 2019

SELL
$1.95 - $2.66 $95 - $130
-49 Closed
0 $0
Q2 2019

Jul 11, 2019

BUY
$2.19 - $3.4 $107 - $166
49 New
49 $0

Others Institutions Holding ALT

About Altimmune, Inc.


  • Ticker ALT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 49,025,300
  • Market Cap $351M
  • Description
  • Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide (proposed INN, formerly known as ALT-801), is a GLP-1/glucagon dual receptor agonist that is in Phase 1b trial for the treatment of obesity and non-alcoholic steatohepatit...
More about ALT
Track This Portfolio

Track Webster Bank, N. A. Portfolio

Follow Webster Bank, N. A. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Webster Bank, N. A., based on Form 13F filings with the SEC.

News

Stay updated on Webster Bank, N. A. with notifications on news.